Cargando…

Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome

Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Ying, Wang, Yan-Li, Xu, Fang, Jia, Xi-Bei, Mu, Su-Hong, Lyu, Hui-Yan, Yuan, Xue-Ying, Na, Shi-Ping, Bao, Yu-Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310221/
https://www.ncbi.nlm.nih.gov/pubmed/35862263
http://dx.doi.org/10.1177/10760296221108967
_version_ 1784753341631299584
author Ji, Ying
Wang, Yan-Li
Xu, Fang
Jia, Xi-Bei
Mu, Su-Hong
Lyu, Hui-Yan
Yuan, Xue-Ying
Na, Shi-Ping
Bao, Yu-Shi
author_facet Ji, Ying
Wang, Yan-Li
Xu, Fang
Jia, Xi-Bei
Mu, Su-Hong
Lyu, Hui-Yan
Yuan, Xue-Ying
Na, Shi-Ping
Bao, Yu-Shi
author_sort Ji, Ying
collection PubMed
description Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = −0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state.
format Online
Article
Text
id pubmed-9310221
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93102212022-07-26 Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome Ji, Ying Wang, Yan-Li Xu, Fang Jia, Xi-Bei Mu, Su-Hong Lyu, Hui-Yan Yuan, Xue-Ying Na, Shi-Ping Bao, Yu-Shi Clin Appl Thromb Hemost Original Manuscript Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = −0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state. SAGE Publications 2022-07-21 /pmc/articles/PMC9310221/ /pubmed/35862263 http://dx.doi.org/10.1177/10760296221108967 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Manuscript
Ji, Ying
Wang, Yan-Li
Xu, Fang
Jia, Xi-Bei
Mu, Su-Hong
Lyu, Hui-Yan
Yuan, Xue-Ying
Na, Shi-Ping
Bao, Yu-Shi
Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
title Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
title_full Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
title_fullStr Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
title_full_unstemmed Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
title_short Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
title_sort elevated soluble podoplanin associates with hypercoagulability in patients with nephrotic syndrome
topic Original Manuscript
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310221/
https://www.ncbi.nlm.nih.gov/pubmed/35862263
http://dx.doi.org/10.1177/10760296221108967
work_keys_str_mv AT jiying elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome
AT wangyanli elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome
AT xufang elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome
AT jiaxibei elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome
AT musuhong elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome
AT lyuhuiyan elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome
AT yuanxueying elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome
AT nashiping elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome
AT baoyushi elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome